IMU Stock Discussion
Imugene Limited Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
Industry: Biotechnology
Keywords: Health Gas Medicine Pharmaceutical Cancer Clinical Trial Biopharmaceutical Cancers Therapy Breast Cancer Oncology Tumor Tumors Biotechnology Companies Cancer Immunotherapy Health Technologies Antibodies Cancer Treatments Her2/Neu Immunotherapy Metastatic Breast Cancer Pancreatic Cancers
Recent Comments
- SwingTradeBot on Market Recap for Wednesday, February 28, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
- SwingTradeBot on Market Recap for Friday, February 23, 2024
- SwingTradeBot on Market Recap for Thursday, February 22, 2024
From the Blog
Featured Articles